129 related articles for article (PubMed ID: 12413824)
1. Profile - Robert Jackson interviewed by Suzanne Berry.
Jackson R
Trends Biotechnol; 2002 Nov; 20(11):485-6. PubMed ID: 12413824
[No Abstract] [Full Text] [Related]
2. Unlocking the money-making potential of RNAi.
Howard K
Nat Biotechnol; 2003 Dec; 21(12):1441-6. PubMed ID: 14647324
[No Abstract] [Full Text] [Related]
3. Gene therapy: cursed or inching towards credibility?
Branca MA
Nat Biotechnol; 2005 May; 23(5):519-21. PubMed ID: 15877060
[No Abstract] [Full Text] [Related]
4. Recent patent applications in DNA synthesis.
Nat Biotechnol; 2007 Jun; 25(6):642. PubMed ID: 17557097
[No Abstract] [Full Text] [Related]
5. Recent patent applications in microRNAs.
Nat Biotechnol; 2006 Jan; 24(1):44. PubMed ID: 16404392
[No Abstract] [Full Text] [Related]
6. Pharmaceutical industry must take its medicine.
Macilwain C
Nature; 2011 Feb; 470(7333):141. PubMed ID: 21307893
[No Abstract] [Full Text] [Related]
7. The future of gene therapy in the UK.
Seymour LW
Trends Biotechnol; 2006 Aug; 24(8):347-9. PubMed ID: 16782218
[TBL] [Abstract][Full Text] [Related]
8. A partial summary of university-industry relationships in the United States.
Zinder ND; Winn J
Recomb DNA Tech Bull; 1984 Mar; 7(1):8-19. PubMed ID: 6587447
[No Abstract] [Full Text] [Related]
9. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.
Liu TC; Hwang TH; Bell JC; Kirn DH
Mol Ther; 2008 Jun; 16(6):1006-8. PubMed ID: 18500240
[No Abstract] [Full Text] [Related]
10. UK industry consolidation is slow despite big merger.
Mitchell P
Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
[No Abstract] [Full Text] [Related]
11. Genaissance pharmaceuticals, inc.
Oestreicher P
Pharmacogenomics; 2002 Mar; 3(2):273-6. PubMed ID: 11972448
[TBL] [Abstract][Full Text] [Related]
12. Andrew Gearing. Interview by Suzanne Berry.
Berry S
Trends Biotechnol; 2002 Sep; 20(9):404-5. PubMed ID: 12175773
[No Abstract] [Full Text] [Related]
13. TPA patent battle rages in United Kingdom.
Johnston K
Nature; 1987 Jun 11-17; 327(6122):450. PubMed ID: 3108671
[No Abstract] [Full Text] [Related]
14. Antisoma-Roche deal--a new kind of buyout?
Mitchell P
Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
[No Abstract] [Full Text] [Related]
15. Urgency to rein in the gene-editing technology.
Zhang X
Protein Cell; 2015 May; 6(5):313. PubMed ID: 26131459
[No Abstract] [Full Text] [Related]
16. Pharmaceutical industry guide. Bitter pills.
Bryan J
Health Serv J; 2002 Nov; 112(5833):suppl 1-3. PubMed ID: 12478709
[No Abstract] [Full Text] [Related]
17. Patent law--claim construction--U.S. District Court for the District of Massachusetts finds conflict on Federal Circuit and holds that product-by-process claims are not limited by their process steps. -- Trustees of Columbia University v. Roche Diagnostics GmbH, 126 F. Supp. 2d 16 (D. Mass. 2000).
Harv Law Rev; 2002 Jan; 115(3):923-30. PubMed ID: 11958232
[No Abstract] [Full Text] [Related]
18. Interaction of statisticians with DMCs.
Cuzick J
Stat Med; 2005 May; 24(10):1609. PubMed ID: 15880514
[No Abstract] [Full Text] [Related]
19. Competition: Unlikely partnerships.
Savage N
Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
[No Abstract] [Full Text] [Related]
20. Political activism needed for patent pools for HIV drugs.
Lancet; 2009 Jul; 374(9686):266. PubMed ID: 19632480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
